What are the Thromboembolic Risks of Heart Failure Combined With Chronic or Paroxysmal AF?

Journal of Cardiac Failure

Volumn 16, Issue 4, 2010, Pages 340-347

  Caldwell, Jane Cochrane ^a   Mamas, Mamas A ^a   Neyses, Ludwig ^a   Garratt, Clifford J ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

heart failure; Paroxysmal atrial fibrillation; thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; BETA THROMBOGLOBULIN; CLOPIDOGREL; D DIMER; FIBRINOGEN; FIBRINOPEPTIDE A; PADGEM PROTEIN; THROMBIN ANTITHROMBIN COMPLEX; WARFARIN;

HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; INCIDENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOEMBOLISM;

ANTICOAGULANTS; ATRIAL FIBRILLATION; CHRONIC DISEASE; HEART FAILURE; HUMANS; RISK FACTORS; THROMBOEMBOLISM;

EID: 77950025090     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2009.12.004     Document Type: Review

References (47)

1. Cowie M.R., Mosterd A., Wood D.A., Deckers J.W., Poole-Wilson P.A., Sutton G.C., et al. The epidemiology of heart failure. Eur Heart J 18 (1997) 208-225
2. Chen L.Y., and Shen W.K. Epidemiology of atrial fibrillation: a current perspective. Heart Rhythm 4 (2007) S1-S6
3. Maisel W.H., and Stevenson L.W. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 91 (2003) 2-8
4. Freudenberger R.S., Hellkamp A.S., Halperin J.L., Poole J., Anderson J., Johnson G., et al. Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation 115 (2007) 2637-2641
5. Hart R.G., Pearce L.A., Rothbart R.M., McAnulty J.H., Asinger R.W., and Halperin J.L. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. J Am Coll Cardiol 35 (2000) 183-187
6. Sudlow C.L.M., and Warlow C.P. Comparable studies of the incidence of stroke and its pathological types: results from an international collaboration. Stroke 28 (1997) 491-499
7. Task F.M., Dickstein K., Cohen-Solal A., Filippatos G., McMurray J.J.V., Ponikowski P., et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 29 (2008) 2388-2442
8. Writing C., Hunt S.A., Abraham W.T., Chin M.H., Feldman A.M., Francis G.S., et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation. Circulation 119 (2009) e391-e479
9. Singer D.E., Albers G.W., Dalen J.E., Fang M.C., Go A.S., Halperin J.L., et al. Antithrombotic therapy in atrial fibrillation. Chest 133 (2008) 546S-592S
10. Fuster V., Ryden L.E., Cannom D.S., Crijns H.J., Curtis A.B., Ellenbogen K.A., et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114 (2006) e257-e354
11. Yamamoto K., Ikeda U., Furuhashi K., Irokawa M., Nakayama T., and Shimada K. The coagulation system is activated in idiopathic cardiomyopathy. J Am Coll Cardiol 25 (1995) 1634-1640
12. Jafri S.M., Ozawa T., Mammen E., Levine T.B., Johnson C., and Goldstein S. Platelet function, thrombin and fibrinolytic activity in patients with heart failure. Eur Heart J 14 (1993) 205-212
13. Gibbs C.R., Blann A.D., Watson R.D.S., and Lip G.Y.H. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: Effects of angiotensin-converting enzyme inhibitor and b-blocker therapy. Circulation 103 (2001) 1746-1751
14. Mehta J., and Mehta P. Platelet function studies in heart disease. VI. Enhanced platelet aggregate formation activity in congestive heart failure: inhibition by sodium nitroprusside. Circulation 60 (1979) 497-503
15. Chong A.Y., Freestone B., Patel J., Lim H.S., Hughes E., Blann A.D., et al. Endothelial activation, dysfunction, and damage in congestive heart failure and the relation to brain natriuretic peptide and outcomes. Am J Cardiol 97 (2006) 671-675
16. Dries M.D., Rosenberg M.D., Waclawiw P., and Domanski M.D. Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the Studies of Left Ventricular Dysfunction Trials. J Am Coll Cardiol 29 (1997) 1074-1080
17. Loh E., Sutton M.S., Wun C.C., Rouleau J.L., Flaker G.C., Gottlieb S.S., et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 336 (1997) 251-257
18. Schmidt R., Fazekas F., Offenbacher H., Dusleag J., and Lechner H. Brain magnetic resonance imaging and neuropsychologic evaluation of patients with idiopathic dilated cardiomyopathy. Stroke 22 (1991) 195-199
19. Vogels R.L., van der Flier W.M., van Harten B., Gouw A.A., Scheltens P., Schroeder-Tanka J.M., et al. Brain magnetic resonance imaging abnormalities in patients with heart failure. Eur J Heart Fail 9 (2007) 1003-1009
20. Murphy N.F., Simpson C.R., Jhund P.S., Stewart S., Kirkpatrick M., Chalmers J., et al. A national survey of the prevalence, incidence, primary care burden and treatment of atrial fibrillation in Scotland. Heart 93 (2007) 606-612
21. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 325 (1991) 293-302
22. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 316 (1987) 1429-1435
23. Pai R.G., and Varadarajan P. Prognostic significance of atrial fibrillation is a function of left ventricular ejection fraction. Clin Cardiol 30 (2007) 349-354
24. Mamas M.A., Caldwell J.C., Chacko S., Garratt C.J., Fath-Ordoubadi F., and Neyses L. A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur J Heart Fail 11 (2009) 676-683
25. Dries D.L., Exner D.V., Gersh B.J., Domanski M.J., Waclawiw M.A., and Stevenson L.W. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. J Am Coll Cardiol 32 (1998) 695-703
26. Olsson L.G., Swedberg K., Ducharme A., Granger C.B., Michelson E.L., McMurray J.J.V., et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 47 (2006) 1997-2004
27. Mathew J., Hunsberger S., Fleg J., Mc Sherry F., Williford W., and Yusuf S. Incidence, predictive factors, and prognostic significance of supraventricular tachyarrhythmias in congestive heart failure. Chest 118 (2000) 914-922
28. Carson P.E., Johnson G.R., Dunkman W.B., Fletcher R.D., Farrell L., and Cohn J.N. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group. Circulation 87 (1993) VI102-VI110
29. Swedberg K., Olsson L.G., Charlesworth A., Cleland J., Hanrath P., Komajda M., et al. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. Eur Heart J 26 (2005) 1303-1308
30. Anderson D.C., Asinger R.W., Newburg S.M., Fanner C.C., Wang K., Bundlie S.R., et al. Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. Ann Int Med 116 (1992) 6-12
31. Corell P., Gustafsson F., Mehlsen J., Rosenberg J., and Hildebrandt P. Paroxysmal atrial fibrillation is uncommon in outpatients with chronic heart failure. Scand Cardiovasc J 42 (2008) 202-207
32. Caldwell J.C., Contractor H., Petkar S., Ali R., Clarke B., Garratt C.J., et al. Atrial fibrillation is under recognised in chronic heart failure - Insights from a heart failure cohort treated with CRT therapy. Europace 11 (2009) 1295-1300
33. Puglisi A., Gasparini M., Lunati M., Sassara M., Padeletti L., Landolina M., et al. Persistent atrial fibrillation worsens heart rate variability, activity and heart rate, as shown by a continuous monitoring by implantable biventricular pacemakers in heart failure patients. J Cardiovasc Electrophysiol 19 (2008) 693-701
34. Hohnloser S.H., Pajitnev D., Pogue J., Healey J.S., Pfeffer M.A., Yusuf S., et al. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W substudy. J Am Coll Cardiol 50 (2007) 2156-2161
35. Capucci A., Santini M., Padeletti L., Gulizia M., Botto G., Boriani G., et al. Monitored atrial fibrillation duration predicts arterial embolic events in patients suffering from bradycardia and atrial fibrillation implanted with antitachycardia pacemakers. J Am Coll Cardiol 46 (2005) 1913-1920
36. Glotzer T.V., Daoud E.G., Wyse D.G., Singer D.E., Holbrook R., Pruett K., et al. Rationale and design of a prospective study of the clinical significance of atrial arrhythmias detected by implanted device diagnostics: the TRENDS study. J Interv Card Electrophysiol 15 (2006) 9-14
37. Hohnloser H., Capucci A., Fain E., Gold M.R., Van Gelder I.C., Healey J., et al. ASymptomatic atrial fibrillation and Stroke Evaluation in pacemaker patients and the atrial fibrillation Reduction atrial pacing Trial (ASSERT). Am Heart J 152 (2006) 442-447
38. Dunkman W.B.M., Johnson G.R.M., Carson P.E.M., Bhat G.M., Farrell L.R., Cohn J.N.M., et al. Incidence of thromboembolic events in congestive heart failure. Circulation 87 (1993) VI-94-VI-101
39. Al Khadra A.S., Salem D.N., Rand W.M., Udelson J.E., Smith J.J., and Konstam M.A. Warfarin anticoagulation and survival: a cohort analysis from the studies of Left Ventricular Dysfunction. J Am Coll Cardiol 31 (1998) 749-753
40. Cokkinos D.V., Haralabopoulos G.C., Kostis J.B., and Toutouzas P.K. Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. Eur J Heart Fail 8 (2006) 428-432
41. Cleland J.G., Findlay I., Jafri S., Sutton G., Falk R., Bulpitt C., et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 148 (2004) 157-164
42. Massie B.M., Krol W.F., Ammon S.E., Armstrong P.W., Cleland J.G., Collins J.F., et al. The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics. J Card Fail 10 (2004) 101-112
43. Pullicino P., Thompson J.L.P., Barton B., Levin B., Graham S., and Freudenberger R.S. Warfarin Versus Aspirin in Patients With Reduced Cardiac Ejection Fraction (WARCEF): rationale, objectives, and design. J Cardiac Failure 12 (2006) 39-46
44. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 84 (1991) 527-539
45. Shivkumar K., Jafri S.M., and Gheorghiade M. Antithrombotic therapy in atrial fibrillation: a review of randomized trials with special reference to the stroke prevention in atrial fibrillation II (SPAF II) trial. Prog Cardiovasc Dis 38 (1996) 337-342
46. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 343 (1994) 687-691
47. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 348 (1996) 633-638